文献速递生殖医学产科母胎医学

单囊胚玻璃化复苏移植周期中囊胚活检行胚胎植入前遗传学检测后的母儿结局

Maternal and neonatal outcomes following blastocyst biopsy for PGT in single vitrified-warmed embryo transfer cycles.
PubMed 文献 · Reprod Biomed Online · 2021-07-29

本回顾性队列研究纳入2016年1月至2018年12月共5097个单囊胚玻璃化复苏移植周期,其中活检组2061个周期、未活检组3036个周期。调整混杂因素后,活检组活产率高于未活检组,总妊娠丢失率和早期流产率低于未活检组;两组在性别比及多种母儿不良结局风险上无显著差异。作者认为囊胚活检在短期内可能不增加母儿不良结局风险。

要点

  • 活检组活产率41.1%,高于未活检组35.6%(aOR 1.27,95%CI 1.05-1.54,P=0.012)。
  • 活检组总妊娠丢失率25.4%、早期流产率12.1%,分别低于未活检组的32.2%和17.3%。
  • 两组性别比及妊娠期高血压疾病、妊娠期糖尿病、前置胎盘、低出生体重、出生缺陷等风险无显著差异。

核心结论

  • 囊胚活检在短期内可能不增加母儿不良结局风险。

研究设计与样本

  • 回顾性队列研究,纳入2016年1月至2018年12月的5097个单囊胚玻璃化复苏移植周期,活检组2061个周期、未活检组3036个周期。
  • 比较两组的母儿结局,并调整母亲年龄、母亲体重指数、孕产次、不孕诊断、囊胚移植时机、囊胚质量、内膜准备方案、移植前内膜厚度和治疗年份。
  • 按不同胚胎植入前遗传学检测(PGT)类型进行亚组分析。

主要发现

  • 活检组活产率41.1% vs 未活检组35.6%(aOR 1.27,95%CI 1.05-1.54,P=0.012)。
  • 活检组总妊娠丢失率25.4% vs 未活检组32.2%(aOR 0.69,95%CI 0.52-0.91,P=0.008)。
  • 活检组早期流产率12.1% vs 未活检组17.3%(aOR 0.56,95%CI 0.38-0.83,P=0.004)。
  • 两组性别比以及妊娠期高血压疾病、妊娠期糖尿病、前置胎盘、未足月胎膜早破、低出生体重、极低出生体重、巨大儿、小于胎龄儿、大于胎龄儿和出生缺陷的风险均无显著差异。
  • 基于不同PGT类型的亚组分析显示所有类型均呈相似模式。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does blastocyst biopsy for preimplantation genetic testing (PGT) increase the risk of adverse maternal and neonatal outcomes? STUDY DESIGN: Retrospective cohort study of 5097 single vitrified-warmed blastocyst transfer cycles from January 2016 to December 2018, with 2061 cycles in the biopsied group and 3036 cycles in the unbiopsied group enrolled in the analyses. Maternal and neonatal outcomes were compared between the two groups. RESULTS: The live birth rate in the biopsied group (41.1%) was significantly higher than that in the unbiopsied group (35.6%, adjusted odds ratio [aOR] 1.27, 95% confidence interval [CI] 1.05-1.54, P = 0.012) after adjusting for maternal age, maternal body mass index, gravidity, parity, infertility diagnosis, timing of blastocyst transfer, blastocyst quality, regimen of endometrial preparation, endometrial thickness before transfer and treatment year. The rates of total pregnancy loss (25.4% versus 32.2%, aOR 0.69, 95% CI 0.52-0.91, P = 0.008) and early miscarriage (12.1% versus 17.3%, aOR 0.56, 95% CI 0.38-0.83, P = 0.004) were significantly lower in the biopsied group than in the unbiopsied group. No significant differences were found in sex ratio or the risks of hypertensive disorders in pregnancy, diabetes in pregnancy, placenta previa, preterm premature rupture of membranes, low birthweight, very low birthweight, macrosomia, small for gestational age, large for gestational age or birth defects between the two groups. When the subgroup analyses were conducted based on different types of PGT, similar patterns were found for all types. CONCLUSION: Blastocyst biopsy might not increase the risks of adverse maternal and neonatal outcomes in the short term.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Hao Y, Long X, Kong F, et al. Maternal and neonatal outcomes following blastocyst biopsy for PGT in single vitrified-warmed embryo transfer cycles. Reprod Biomed Online. 2021. PMID: 34866000. doi:10.1016/j.rbmo.2021.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。